Online inquiry

IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4677MR)

This product GTTS-WQ4677MR is a type of mRNA modified with 5-Methyl-CTP, which ecodes the monoclonal antibody that targets MSTN gene. The antibody can be applied in Duchenne muscular dystrophy (DMD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005259.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2660
UniProt ID O14793
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ4677MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10032MR IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA L19-131 I
GTTS-WQ9791MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA JS002
GTTS-WQ14923MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ1451MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ12470MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA NN-8226
GTTS-WQ2921MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG888
GTTS-WQ15619MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA VAY-736
GTTS-WQ13908MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN2477
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW